The FDA has issued priority review vouchers tied to three psychedelic programs, as part of the Trump administration’s push to expand access to mental health treatments. The agency’s announcement covers Compass Pathways’ psilocybin therapy for treatment-resistant depression, Usona Institute’s psilocybin-like program for major depressive disorder, and a Transcend Therapeutics candidate for PTSD. In a separate update, the FDA unveiled commissioner’s national priority vouchers for three psychedelic companies. The selections were described as a surprise by market participants, and the FDA identified the voucher-receiving products rather than naming all sponsor companies in the disclosure. Compass confirmed receipt of a voucher, while other recipients were described as identified by people familiar with the matter. The vouchers could allow faster FDA review timelines and—depending on the specific program rules—additional downstream commercial value for sponsors. The move affects developers that are already in late-stage development for psychiatric endpoints, while it also underscores how policy decisions can materially change regulatory cadence in a high-uncertainty segment of the pipeline.